3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
4
Sarcoma
1
Conditions
Sarcoma
1
Neoplasm Metastasis
1
Melanoma
1
Interventions
Cyclophosphamide
20
pembrolizumab
19
Nivolumab
10
fludarabine
7
Radiosurgery
7
Specimen Handling
6
Ipilimumab
6
Injections
5
Celecoxib
5
poly ICLC
4
Radiation
4
Paclitaxel
4
Melphalan
4
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Docetaxel
4
Cryosurgery
4
durvalumab
3
cemiplimab
3
Filgrastim
3
Etoposide
3
Cisplatin
3
Blood Specimen Collection
3
Biopsy
3
trastuzumab deruxtecan
2
tislelizumab
2
talimogene laherparepvec
2
spartalizumab
2
fludarabine phosphate
2
bempegaldesleukin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
IMM-101
×
Sarcoma
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts